149 related articles for article (PubMed ID: 22020317)
21. Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Sueda T; Kudo T; Sakai D; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Ezoe S; Matsumoto K; Doki Y; Mori M; Satoh T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1321-4. PubMed ID: 25374410
[TBL] [Abstract][Full Text] [Related]
22. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
23. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
24. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
[TBL] [Abstract][Full Text] [Related]
25. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
27. [Phase I study of S-1. S-1 Study Group].
Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
[TBL] [Abstract][Full Text] [Related]
28. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
29. [Clinical benefit of S-1 in metastatic breast cancer].
Saeki T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():202-6. PubMed ID: 16898003
[TBL] [Abstract][Full Text] [Related]
30. S-1 as a core anticancer fluoropyrimidine agent.
Miura K; Shirasaka T; Yamaue H; Sasaki I
Expert Opin Drug Deliv; 2012 Mar; 9(3):273-86. PubMed ID: 22235991
[TBL] [Abstract][Full Text] [Related]
31. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Liu HY; Ding L; Yu Y; Chu Y; Zhu H
Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
[TBL] [Abstract][Full Text] [Related]
33. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
36. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
[TBL] [Abstract][Full Text] [Related]
37. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
38. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
[TBL] [Abstract][Full Text] [Related]
39. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
[TBL] [Abstract][Full Text] [Related]
40. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
